Market closedNon-fractional

Pulmonx/LUNG

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Ticker

LUNG

Sector

Healthcare

Trading on

NASDAQ

Industry

Health Care Equipment and Supplies

Headquarters

Redwood City, United States

Employees

279

Pulmonx Metrics

BasicAdvanced
$252M
Market cap
-
P/E ratio
-$1.54
EPS
0.66
Beta
-
Dividend rate
$252M
0.66
6.947
5.979
29.55
36.718
-16.95%
-20.52%
-46.17%
3.4
2.26
2.31
-6.538
27.14%
-2.86%
29.82%
-8.82%

What the Analysts think about Pulmonx

Analyst Ratings

Majority rating from 5 analysts.
Buy

Pulmonx Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-72.87% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$19M
-2.08%
Net income
-$14M
-0.72%
Profit margin
-72.87%
1.39%

Pulmonx Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.98%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.43
-$0.39
-$0.36
-$0.36
-
Expected
-$0.44
-$0.43
-$0.41
-$0.46
-$0.42
Surprise
-1.56%
-8.84%
-11.58%
-21.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pulmonx stock?

Pulmonx (LUNG) has a market cap of $252M as of July 06, 2024.

What is the P/E ratio for Pulmonx stock?

The price to earnings (P/E) ratio for Pulmonx (LUNG) stock is 0 as of July 06, 2024.

Does Pulmonx stock pay dividends?

No, Pulmonx (LUNG) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Pulmonx dividend payment date?

Pulmonx (LUNG) stock does not pay dividends to its shareholders.

What is the beta indicator for Pulmonx?

Pulmonx (LUNG) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Pulmonx stock

Buy or sell Pulmonx stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing